Wells Fargo resumed coverage of Nevro (NVRO) with an Equal Weight rating and $5 price target Wells believes Nevro is comfortable with consensus implying a return to year over year sales growth in the second half of 2025, though the firm does not see upside to Street estimates, the analyst tells investors in a research note. Easier y/y comps, lessened competitive trialing, AdaptivAI ramp, continued healthy growth in painful diabetic neuropathy, adding new sales territories, and Vyrsa ramping could support 2025 growth, the firm says.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVRO:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue